# US 2005/0038007 A1 · Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0038007 A1
- Document ID: US20050038007A1
- Status: Published application
- Kind: A1
- Application number: 10/903,433
- Filed: 2004-07-30
- Published: 2005-02-17
- Earliest claimed: 2003-08-04
- Assignees: Pfizer Inc.
- Inventors: William Curatolo; Dwayne Friesen; Steven Sutton
- Web page: https://patentgrep.com/patent/US20050038007A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4858: {Organic compounds}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A dosage form comprises a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release of the cholesteryl ester transfer protein inhibitor.

## Claims

### Claim 1

A dosage form comprising:
(a) a cholesteryl ester transfer protein inhibitor in a solubility-improved form, and
(b) an HMG-CoA reductase inhibitor;
wherein said dosage form provides immediate release of said HMG-CoA reductase inhibitor and controlled release of said cholesteryl ester transfer protein inhibitor.

### Claim 2 (depends on 1)

The dosage form of claim 1 wherein said dosage form releases in vivo or in vitro at least 80 wt % of said HMG-CoA reductase inhibitor at one hour after administration of said dosage form to an aqueous environment of use.

### Claim 3 (depends on 2)

The dosage form of claim 2 wherein said dosage form releases in vivo or in vitro at least 90 wt % of said HMG-CoA reductase inhibitor at one hour after administration of said dosage form to an aqueous environment of use.

### Claim 4 (depends on 1)

The dosage form of claim 1 wherein said dosage form is a sustained release dosage form that releases in vivo or in vitro 70 wt % of said cholesteryl ester transfer protein inhibitor over 2 hours or more after administration of said dosage form to an aqueous environment of use.

### Claim 5 (depends on 4)

The dosage form of claim 4 wherein said dosage form releases in vivo or in vitro 70 wt % of said cholesteryl ester transfer protein inhibitor over 3 hours or more after administration of said dosage form to an aqueous environment of use.

### Claim 6 (depends on 4)

The dosage form of claim 4 wherein said dosage form releases in vivo or in vitro 70 wt % of said cholesteryl ester transfer protein inhibitor over 4 hours or more after administration of said dosage form to an aqueous environment of use.

### Claim 7 (depends on 1)

The dosage form of claim 1 wherein, following administration to an in vivo use environment, said dosage form provides at least one of:
(i) at least 50% inhibition of plasma cholesteryl ester transfer protein for at least 12 hours;
(ii) a maximum drug concentration in the blood that is less than or equal to 80% of the maximum drug concentration in the blood provided by a dosage form that provides immediate release of the same amount of said solubility-improved form of said cholesteryl ester transfer protein inhibitor;
(iii) a mean HDL cholesterol level after dosing for 8 weeks that is at least about 1.2-fold that obtained prior to dosing; and
(iv) a mean LDL cholesterol level after dosing for 8 weeks that is less than or equal to 90% that obtained prior to dosing.

### Claim 8 (depends on 7)

The dosage form of claim 7 wherein, following administration to an in vivo use environment, said dosage form provides at least two of:
(i) at least 50% inhibition of plasma cholesteryl ester transfer protein for at least 12 hours;
(ii) a maximum drug concentration in the blood that is less than or equal to 80% of the maximum drug concentration in the blood provided by a dosage form that provides immediate release of the same amount of said solubility-improved form of said cholesteryl ester transfer protein inhibitor;
(iii) a mean HDL cholesterol level after dosing for 8 weeks that is at least about 1.2-fold that obtained prior to dosing; and
(iv) a mean LDL cholesterol level after dosing for 8 weeks that is less than or equal to 90% that obtained prior to dosing.

### Claim 9 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises said cholesteryl ester transfer protein inhibitor in the form of a matrix controlled-release device.

### Claim 10 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises said cholesteryl ester transfer protein inhibitor in the form of an osmotic controlled-release device.

### Claim 11 (depends on 10)

The dosage form of claim 10 wherein said osmotic controlled-release device comprises (1) a core, said core comprising said cholesteryl ester transfer protein inhibitor and an osmotic agent, and (2) a non-dissolving, non-eroding coating surrounding said core.

### Claim 12 (depends on 11)

The dosage form of claim 11 wherein said core comprises:
(1) a first composition comprising said cholesteryl ester transfer protein inhibitor; and
(2) a second composition comprising said HMG-CoA reductase inhibitor.

### Claim 13 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises a plurality of controlled-release multiparticulates comprising said cholesteryl ester transfer protein inhibitor.

### Claim 14 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises an immediate release coating comprising said HMG-CoA reductase inhibitor.

### Claim 15 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises an immediate release layer comprising said HMG-CoA reductase inhibitor.

### Claim 16 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises an immediate release composition comprising said HMG-CoA reductase inhibitor.

### Claim 17 (depends on 16)

The dosage form of claim 16 wherein said immediate release composition is selected from the group consisting of a plurality of particles comprising said HMG-CoA reductase inhibitor, a plurality of immediate release multiparticulates comprising said HMG-CoA reductase inhibitor, and a plurality of immediate release granules comprising said HMG-CoA reductase inhibitor.

### Claim 18 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises a capsule, said capsule comprising a controlled-release device comprising said cholesteryl ester transfer protein inhibitor.

### Claim 19 (depends on 1)

The dosage form of claim 1 wherein said dosage form comprises a kit.

### Claim 20 (depends on 19)

The dosage form of claim 19 wherein said kit is selected from the group consisting of a divided container and a divided foil packet.

### Claim 21 (depends on 1)

The dosage form of claim 1 wherein said cholesteryl ester transfer protein inhibitor is selected from the group consisting of the compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, Formula XII, Formula XIII, Formula XIV, Formula XV, Formula XVI, Formula XVII, Formula XVIII and Formula XIX.

### Claim 22 (depends on 21)

The dosage form of claim 21 wherein said cholesteryl ester transfer 15 protein inhibitor is selected from the group consisting of the compounds of Formula IV.

### Claim 23 (depends on 1)

The dosage form of claim 1 wherein said cholesteryl ester transfer protein inhibitor is selected from the group consisting of [2R,4S]-4-[acetyl-(3,5-bis-carboxylic acid isopropyl ester, [2R,4S]-4-[3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol, and [2R,4S]4-[(3,5-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.

### Claim 24 (depends on 1)

The dosage form of claim 1 wherein said cholesteryl ester transfer protein inhibitor is torcetrapib.

### Claim 25 (depends on 1)

The dosage form of claim 1 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, atorvastatin, simvastatin, cerivastatin, rivastatin, mevastatin, velostatin, compactin, dalvastatin, fluindostatin, rosuvastatin, pitivastatin, dihydrocompactin and pharmaceutically acceptable forms thereof.

### Claim 26 (depends on 1)

The dosage form of claim 1 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, the cyclized lactone form of atorvastatin, a 2-hydroxy, 3-hydroxy or 4-hydroxy derivative of said compounds, and a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The dosage form of claim 26 wherein said HMG-CoA reductase inhibitor is atorvastatin hemicalcium trihydrate.

### Claim 28 (depends on 1)

The dosage form of claim 1 comprising torcetrapib and atorvastatin, or pharmaceutically acceptable forms thereof.

### Claim at position 29 (depends on 24)

29 The dosage form of claim 24 wherein, following administration to an in vivo use environment, said dosage form provides a plasma concentration of said torcetrapib of about 70 ng/mL or more for a period of about 12 hr or more.

### Claim 30 (depends on 1)

The dosage form of claim 1 wherein said solubility-improved form is a solid amorphous dispersion comprising said cholesteryl ester transfer protein inhibitor and a polymer.

### Claim 31 (depends on 1)

The dosage form of claim 1 wherein said solubility-improved form is a lipid vehicle comprising said cholesteryl ester transfer protein inhibitor.

### Claim 32 (depends on 1)

The dosage form of claim 1 wherein said solubility-improved form is selected from the group consisting of a solid adsorbate comprising a low-solubility drug adsorbed onto a substrate, nanoparticles, adsorbates of the drug in a crosslinked polymer, a nanosuspension, a supercooled form, a drug/cyclodextrin drug form, a softgel form, a self-emulsifying form, a three-phase drug form, a crystalline highly soluble form, a high-energy crystalline form, a hydrate or solvate crystalline form, an amorphous form, a mixture of said cholesteryl ester transfer protein inhibitor and a solubilizing agent, and a solution of said cholesteryl ester transfer protein inhibitor dissolved in a liquid.

### Claim 33 (depends on 1)

The dosage form of claim 1 wherein said solubility-improved form provides, when administered alone to a use environment, a maximum drug concentration of said cholesteryl ester transfer protein inhibitor that is at least 2-fold that provided by a control composition consisting of an equivalent amount of said cholesteryl ester transfer protein inhibitor in crystalline form alone.

### Claim 34 (depends on 33)

The dosage form of claim 33 wherein said solubility-improved form provides a maximum drug concentration of said cholesteryl ester transfer protein inhibitor that is at least 10-fold that provided by said control composition.

### Claim 35 (depends on 1)

The dosage form of claim 1 wherein said solubility-improved form provides, when administered alone to a use environment, a concentration of said cholesteryl ester transfer protein inhibitor versus time area under the curve (AUC), for any period of at least 90 minutes between the time of introduction into the use environment and about 270 minutes following introduction to the use environment that is at least about 1.25-fold that of a control composition consisting of an equivalent quantity of said cholesteryl ester transfer protein inhibitor in crystalline form alone.

### Claim 36 (depends on 35)

The dosage form of claim 35, wherein said solubility-improved form provides a concentration of said cholesteryl ester transfer protein inhibitor versus time AUC that is at least about 5-fold that of said control composition.

### Claim 37 (depends on 1)

A method for treating atherosclerosis, peripheral vascular disease, dyslipidemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia; the method comprising administering to a mammal in need of treatment, a dosage form of claim 1.
